

## REVIEWER'S REPORT

Manuscript No.: IJAR-52831

Date: 17-07-2025

**Title: Intellectual Property Rights and Public Health: A Critical analysis**

### Recommendation:

**Accept as it is .....YES.....**

Accept after minor revision.....

Accept after major revision .....

Do not accept (*Reasons below*) .....

Rating	Excel.	Good	Fair	Poor
Originality		✓		
Techn. Quality			✓	
Clarity		✓		
Significance		✓		

Reviewer Name: Dr Abdul Hameed Shah

### Reviewer's Comment for Publication.

### Abstract Evaluation:

The abstract effectively addresses the central issue of balancing intellectual property rights (IPR) with the imperatives of public health. It outlines the dual impact of IPR: on one hand, stimulating pharmaceutical innovation and economic growth, and on the other, potentially limiting access to essential medicines due to high costs and monopolistic control.

The abstract presents a well-articulated argument on how patents—particularly under the framework of international agreements like TRIPS—can influence medicine availability and affordability. The role of compulsory licensing as a policy instrument to mitigate these challenges is clearly introduced, and its significance in the Indian context is appropriately emphasized. The mention of real-life examples and the COVID-19 crisis grounds the discussion in current global health realities and illustrates the relevance of IPR in emergency scenarios.

The closing remarks advocate for a balanced IPR regime that nurtures innovation while prioritizing equitable access to healthcare, which aligns well with global discussions on the ethics of pharmaceutical patents and access to medicines.

### Introduction Evaluation:

The introduction clearly defines the scope of both Intellectual Property Rights and public health. It succinctly outlines the inherent tension between protecting pharmaceutical innovations and ensuring public access to affordable treatments. The explanation is accessible and effectively sets the stage for a critical analysis of how patent regimes intersect with healthcare access, particularly in developing countries.

The introduction provides a solid contextual foundation for the subsequent discussion, articulating the broader policy and ethical concerns that arise when life-saving treatments are restricted due to patent

# International Journal of Advanced Research

**Publisher's Name: Jana Publication and Research LLP**

*www.journalijar.com*

---

## **REVIEWER'S REPORT**

protections. The focus on developing countries and the implications of delayed access to generics are particularly relevant in the current global health landscape.

### **Overall Assessment:**

The abstract and introduction collectively frame a pertinent and timely investigation into the intersection of IPR and public health. The paper promises a balanced, evidence-based exploration of legal frameworks, practical applications like compulsory licensing, and their broader implications for access to medicines. It reflects both legal and humanitarian concerns, demonstrating a comprehensive understanding of the subject matter and a commitment to examining policy in a socially responsible context.